Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Constipation and BRCA1[original query] |
---|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC cancer 2022 12 22 (1): 1343. Mahtani Reshma, Niyazov Alexander, Arondekar Bhakti, Lewis Katie, Rider Alex, Massey Lucy, Lux Michael Patri |
- Page last reviewed:Feb 1, 2024
- Content source: